u/sena_teixeira

the muscle cramps that arrives at week 89 out of nowhere is usually something else

Nothing here is medical or legal advice, and eligibility questions have national answers that a pharmacist where you live can give you in minutes.

Careful. What you are describing is a delayed shipment, and this board should not turn that into an accusation without more.

Went looking for trial data on the specific question asked here and found the population had not been enrolled.

The thing that surprised me was how much of the discussion here is inference rather than measurement.

the reimbursement criteria are published in most member states

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.

Yes — the day-two-to-day-four window is so consistent across this board that it is almost diagnostic.

Not convinced by that mechanism. Slowed gastric emptying explains fullness and reflux; it does not explain what you are describing.

That reads as a titration plan for an unapproved compound.

heart_rate_bump is right about the escalation being the variable. It explains most of the difficult reports here.

Careful with the rankings. A phase 2 result and a phase 3 result are not on the same evidential footing and cannot be listed in one table.

Small fix — those two prices are for different pack sizes, which accounts for most of the gap.

Is this a PCOS diagnosis or an insulin resistance finding?

Is that a weight number from a different programme?

nothing here is available as a prescription product, so read every thread with that in mind

Which endpoint — histological response, fibrosis improvement, or fat fraction?

fibrosis improvement without worsening steatohepatitis is the phrase to learn

Correcting my own comment above: I said day three and my log says day two. Same pattern, wrong day.

Nothing in this thread is medical advice, including this comment. I am describing a mechanism, not telling anybody what to do about their own week.

Small fix — the name you are describing is in the wider-market table with almost nothing on file, not in the documented twenty.

Adding the practical version: buy small from anyone new, test it, then decide.

Not convinced by that mechanism. Slowed gastric emptying explains fullness and reflux; it does not explain what you are describing.

not approved anywhere, and the boards forget that constantly

Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.

hair shedding follows the weight loss, not the drug, and it stops

Is that a weight number from a different programme?

Correction: that is the imaging endpoint, not the histological one. The paper reports both and they differ substantially.

Careful, that guidance is from a different country and this thread is asking about somewhere else entirely.

Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.

Agreed on the heart-rate reports. They are consistent enough across the threads to be worth noting, not enough to be a finding.

Careful with the supplement recommendation. There is no evidence for it here and the mechanism you are proposing does not hold.

Never name an individual. The sidebar rule exists because the cost of being wrong falls on a person and the benefit of being right falls on nobody in particular.

I would not treat one pharmacy’s quote as a national price. The variation within a country is often larger than between them.

Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use.

a rough fortnight at each step is normal, a rough three months is not

Are you tracking heart rate at all?

This. The phase 2 result was genuinely large and it was also 48 weeks in a few hundred people.

That is body weight change, not fat mass. The trials report the first and people quote it as the second.

Correction: that is a known effect of reduced intake rather than a direct drug effect. The distinction matters because the fix is different.